Leerink Partnrs Has Negative Outlook of ELDN FY2025 Earnings

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – Investment analysts at Leerink Partnrs decreased their FY2025 earnings per share (EPS) estimates for Eledon Pharmaceuticals in a research report issued on Sunday, March 23rd. Leerink Partnrs analyst T. Smith now anticipates that the company will post earnings per share of ($1.14) for the year, down from their prior forecast of ($1.02). The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.81) per share. Leerink Partnrs also issued estimates for Eledon Pharmaceuticals’ FY2026 earnings at ($1.11) EPS, FY2027 earnings at ($1.38) EPS, FY2028 earnings at ($1.36) EPS and FY2029 earnings at ($0.67) EPS.

Separately, Guggenheim began coverage on Eledon Pharmaceuticals in a research note on Tuesday, January 28th. They set a “buy” rating and a $9.00 price target on the stock.

Eledon Pharmaceuticals Stock Performance

Shares of ELDN opened at $3.47 on Wednesday. Eledon Pharmaceuticals has a 1 year low of $1.52 and a 1 year high of $5.54. The company’s 50 day simple moving average is $4.15 and its 200 day simple moving average is $3.89. The company has a market capitalization of $207.79 million, a price-to-earnings ratio of -1.73 and a beta of 0.80.

Eledon Pharmaceuticals (NASDAQ:ELDN) last released its quarterly earnings results on Thursday, March 20th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.32). During the same period in the prior year, the business earned ($1.00) EPS.

Institutional Trading of Eledon Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jefferies Financial Group Inc. acquired a new stake in shares of Eledon Pharmaceuticals in the fourth quarter worth approximately $91,000. Alpine Global Management LLC acquired a new position in shares of Eledon Pharmaceuticals in the 4th quarter valued at $56,000. AWM Investment Company Inc. acquired a new stake in shares of Eledon Pharmaceuticals during the 4th quarter worth $4,534,000. Frazier Life Sciences Management L.P. purchased a new position in shares of Eledon Pharmaceuticals in the 4th quarter worth $4,848,000. Finally, Woodline Partners LP raised its position in shares of Eledon Pharmaceuticals by 98.3% in the 4th quarter. Woodline Partners LP now owns 1,671,822 shares of the company’s stock worth $6,888,000 after buying an additional 828,930 shares during the period. Hedge funds and other institutional investors own 56.77% of the company’s stock.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).